An independent private company with international collaboration experience
Affilogic is an independent private company established in Nantes in 2010 and specialized in the discovery, development and combination of Nanofitins® for therapeutic applications. Affilogic moved in February 2022 in new, larger facilities (2000m2), fully equipped for Nanofitin® discovery and early development, including non-GMP production.
Its operations are currently largely conducted through international collaborations with pharma and biotech companies, and through internal R&D programs, for some of them partially sponsored by public funding (France Relance/ French Government, Eurostars / European Commission and BPI, FEDER React EU / European Commission and Région Pays de La Loire…).
Affilogic is also extremely well integrated in its local environment, as a major member of the Atlanpole Biotherapies cluster in Nantes, one of the few French bio-clusters recognized by the government for its specific expertise in biotherapies and development of biotherapeutics. The company has signed a general collaboration framework agreement with the University of Nantes.
Based on an innovative technology and a strong intellectual property portfolio
For any biological target, from peptides to entire cells, it is possible to generate custom Nanofitins® with a high binding affinity and controlled specificity for detection, capture, targeting or interacting purposes. Affilogic has exclusive and worldwide rights to this technology from the Pasteur Institute and the CNRS and performs custom discovery, development and combination of Nanofitins® against targets nominated by its partners thanks to a proprietary discovery process. Affilogic completed this strong intellectual property position by generating a portfolio of 11 fully owned patent families to date.
